{
  "nctId": "NCT00085982",
  "briefTitle": "Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance",
  "officialTitle": "Phase II Trial of Effect of Metreleptin Therapy in Severe Insulin Resistance",
  "protocolDocument": {
    "nctId": "NCT00085982",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-05-05",
    "uploadDate": "2021-11-12T12:01",
    "size": 716974,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00085982/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 11,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2003-08-21",
    "completionDate": "2030-01-01",
    "primaryCompletionDate": "2019-10-23",
    "firstSubmitDate": "2004-06-18",
    "firstPostDate": "2004-06-21"
  },
  "eligibilityCriteria": {
    "criteria": "* INCLUSION CRITERIA:\n* Provision of signed and dated informed consent form\n* Male or female, aged \\> 5 years\n* Clinically significant, severe insulin resistance caused by a known or suspected defect in the insulin receptor\n* Presence of at least one of the following metabolic abnormalities:\n\n  * Fasting insulin \\>30 micro U/ml, or\n  * Presence of diabetes as defined by the 2006 American Diabetes Association (ADA) criteria:\n\n    * Fasting plasma glucose \\>= 126 mg/dL\n    * 2 hour plasma glucose \\>= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load, or\n    * Diabetic symptoms with a random plasma glucose \\>= 200 mg/dL\n\nEXCLUSION CRITERIA:\n\n* Pregnant at time of enrollment, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.\n* Known infectious liver disease\n* Known HIV infection\n* Current alcohol or substance abuse\n* Active tuberculosis\n* Use of anorexigenic drugs\n* Other conditions which in the opinion of the clinical investigators would impede completion of the study.\n* Subjects who have a known hypersensitivity to E. Coli derived proteins.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "5 Years",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in HbA1C",
        "description": "Change in HbA1C at month 12 from baseline.",
        "timeFrame": "Change at month 12 from baseline"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Fasting Insulin Level",
        "description": "Change in fasting insulin level at month 12 from baseline",
        "timeFrame": "Change at month 12 from baseline"
      },
      {
        "measure": "Change in Fasting Blood Glucose",
        "description": "Change in fasting blood glucose at month 12 from baseline.",
        "timeFrame": "Change at month 12 from baseline"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 24,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:29:10.962Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}